A bare metal stent (31100, 40200, 42300, 44400) with drug eluting reservoirs for implantation into a tubular organ of a living organism comprising: an elongated tubular structure having a luminal surface and an abluminal surface, the elongated tubular structure including a plurality of interconnected elements, a portion of the interconnected elements comprising at least one reservoir wherein each reservoir opens at the luminal surface and the abluminal surface and has a volume; at least one base composition inlay comprising PLGA deposited in the at least one reservoir proximate the luminal surface, and below the abluminal surface, of the elongated tubular structure; and at least one top composition inlay comprising PLGA, BHT and a therapeutic agent deposited in the reservoir on top of the base composition inlay, characterized in that the therapeutic agent comprises rapamycin and in that the at least one top composition inlay is below the abluminal surface of the elongated tubular structure, and the at least one base composition inlay and the at least one top composition inlay form a reservoir inlay within the at least one reservoir, the reservoir inlay occupying between seventy-six and eighty-eight percent of the volume of the at least one reservoir and having a top surface below the abluminal surface of the stent such that, upon implantation, approximately seventy-five percent of the abluminal surface is bare metal and approximately twenty-five percent of the abluminal surface comprises the reservoirs with the at least one base composition inlay and the at least one top composition inlay and at approximately ninety days post implantation there is no at least one base composition inlay and no at least one top composition inlay. an elongated tubular structure having a luminal surface and an abluminal surface, the elongated tubular structure including a plurality of interconnected elements, a portion of the interconnected elements comprising at least one reservoir wherein each reservoir opens at the luminal surface and the abluminal surface and has a volume; at least one base composition inlay comprising PLGA deposited in the at least one reservoir proximate the luminal surface, and below the abluminal surface, of the elongated tubular structure; and at least one top composition inlay comprising PLGA, BHT and a therapeutic agent deposited in the reservoir on top of the base composition inlay, characterized in that the therapeutic agent comprises rapamycin and in that the at least one top composition inlay is below the abluminal surface of the elongated tubular structure, and the at least one base composition inlay and the at least one top composition inlay form a reservoir inlay within the at least one reservoir, the reservoir inlay occupying between seventy-six and eighty-eight percent of the volume of the at least one reservoir and having a top surface below the abluminal surface of the stent such that, upon implantation, approximately seventy-five percent of the abluminal surface is bare metal and approximately twenty-five percent of the abluminal surface comprises the reservoirs with the at least one base composition inlay and the at least one top composition inlay and at approximately ninety days post implantation there is no at least one base composition inlay and no at least one top composition inlay.